ddPCR: 74% concordance rate between cfDNA and tissueSurvival: Longer PFS and OS for patients with EGFR mutations in cfDNA and tumor samples versus EGFR mutations only in tumor (Median: PFS: 12.6 months versus 6.7 months; OS: 35.6 months versus 23.8 months)ddPCR and NGS: Limit of quantification: 0.04% for ddPCR, 5% for NGS; NGS had 89% sens. and 100% spec. This evidence concerns the gene EGFR and neoplasm.